Syntenin评估三阴性乳腺癌患者新辅助化疗疗效的研究  

Study of Syntenin Evaluation of the Efficacy of Neoadjuvant Chemotherapy in Patients with Negative Breast Cancer

作　　者：余小婷 汤杰 姜芳倩 翁文娟 Yu Xiaoting;Tang Jie;Jiang Fangqian(The First Affiliated Hospital of Bengbu Medical University,Bengbu,Anhui,233004,China)

机构地区：[1]蚌埠医科大学第一附属医院,安徽蚌埠233004

出　　处：《黑龙江医学》2025年第4期422-425,共4页Heilongjiang Medical Journal

基　　金：蚌埠医学院自然科学重点项目(2021byzd165)。

摘　　要：目的:采用配体蛋白聚糖结合蛋白(Syntenin)评估三阴性乳腺癌(TNBC)患者新辅助化疗(NAC)疗效,旨在探讨Syntenin是否可成为评估NAC疗效的生物标志物。方法:选取2020年12月-2021年12月蚌埠医科大学第一附属医院收治的132例TNBC并实施NAC的患者作为研究对象,根据Syntenin表达量将其分为阴性组60例和阳性组72例。收集患者月经状况、肿瘤直径、淋巴结分期、TNM分期、Ki67表达临床数据,进行统计分析。结果:NAC前,阳性组患者72例,阴性组患者60例;NAC后,阳性组患者减少至37例,阴性组患者增加至95例。两组患者NAC前后Syntenin表达率比较,差异有统计学意义(χ^(2)=19.142,P<0.001)。NAC前,两组患者绝经状况比较,差异无统计学意义(χ^(2)=0.666,P>0.05);两组患者肿瘤直径、淋巴结分期、TNM分期及Ki67指数比较,差异均有统计学意义(χ^(2)=22.172、2.626、8.765、4.440,P<0.05)。NAC后,两组患者绝经状况、肿瘤直径、淋巴结分期及TNM分期比较,差异均无统计学意义(χ^(2)=0.241、2.347、0.845、0.233,P>0.05);两组患者Ki67指数比较,差异有统计学意义(χ^(2)=4.067,P<0.05)。NAC前Syntenin表达、肿瘤直径及淋巴结分期评估有效、无效情况比较,差异均有统计学意义(χ^(2)=7.557、7.137、4.898,P<0.05)。结论:Syntenin表达在NAC后表达明显下降,Syntenin表达与肿瘤直径、淋巴结分期及Ki67指数密切相关,监测NAC过程中的Syntenin表达可作为NAC疗效的生物标志物。Objective:To study the expression characteristics and clinical features of ligand protein syndecan-binding protein(Syntenin)in triple-negative breast cancer(TNBC),and evaluate whether Syntenin protein can serve as a biomarker for NAC efficacy.Methods:A total of 132 patients with triple-negative breast cancer who underwent neoadjuvant therapy from December 2020 to December 2021 were selected.According to the expression level of Syntenin,60 cases were divided into negative group,and 72 cases were positive group.Clinical data of menstrual status,tumor diameter,lymph node stage,TNM stage and Ki67 expression were collected for statistical analysis.Results:Before NAC,there were 72 patients in positive group and 60 patients in negative group.After NAC,the number of patients decreased to 37 in the positive group and increased to 95 in the negative group.The expression rate of Syntenin before and after NAC was significantly different between the two groups(χ^(2)=19.142,P<0.001).Before NAC,there was no significant difference in menopausal status between the two groups(χ^(2)=0.666,P>0.05).There were significant differences in tumor diameter,lymph node stage,TNM stage and Ki67 index between the two groups(χ^(2)=22.172,2.626,8.765,4.440;P<0.05).After NAC,there were no significant differences in menopausal status,tumor diameter,lymph node stage and TNM stage between the two groups(χ^(2)=0.241,2.347,0.845,0.233;P>0.05).There was significant difference in Ki67 index between the two groups(χ^(2)=4.067,P<0.05).There were significant differences in the expression of pre-NAC Syntenin,tumor diameter and lymph node staging(χ^(2)=7.557,7.137,4.898;P<0.05).Conclusion:Syntenin expression decreases significantly after NAC,and is closely related to tumor diameter,lymph node stage and Ki67 index.Monitoring Syntenin expression during NAC can be used as a biomarker of NAC efficacy.

关 键 词：配体蛋白聚糖结合蛋白 三阴性乳腺癌 新辅助化疗 预后 

分 类 号：R737.9[医药卫生—肿瘤]